口服罗氟司特对银屑病患者体重及心血管代谢指标的影响:PSORRO随机对照试验事后分析
罗氟司特组第12周和第24周体重中位变化分别为-2.6%和-4%,安慰剂组分别为0.0%和1.3%,且罗氟司特组食欲下降更常见,血压和实验室检查无变化。
要点
- 罗氟司特组第12周体重中位下降2.6%,第24周下降4%。
- 安慰剂组第12周体重变化0.0%,第24周增加1.3%。
- 罗氟司特组食欲下降更常见,血压和实验室检查无变化。
核心结论
- 口服罗氟司特可诱导体重下降和食欲减退,支持其作为银屑病有吸引力的治疗选择。
研究设计与样本
- PSORRO研究的事后分析,中重度斑块状银屑病患者随机1:1接受口服罗氟司特500 μg每日一次或安慰剂12周,随后两组开放标签治疗至24周。
主要发现
- 罗氟司特组第12周和第24周体重中位变化分别为-2.6%和-4%。
- 初始安慰剂组第12周和第24周体重中位变化分别为0.0%和1.3%。
- 罗氟司特组食欲下降更频繁,未观察到血压或实验室检查变化。
临床怎么用
- 对于合并超重或肥胖的银屑病患者,口服罗氟司特可能同时带来体重下降的额外获益。
局限性
- 事后分析且样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Weight loss is reported with oral roflumilast, which is approved for chronic obstructive pulmonary disease (COPD). Recently, the drug has shown efficacy in psoriasis, a disease strongly linked to overweight/obesity. OBJECTIVE: To describe the effects of oral roflumilast on body weight and cardio-metabolic parameters in patients with psoriasis. METHODS: Posthoc analyses from the PSORRO study, where patients with moderate-to-severe plaque psoriasis were randomized 1:1 to oral roflumilast 500 μg once-daily or placebo for 12 weeks, followed by active, open-label treatment through week 24 in both groups. Changes in body weight, blood pressure, gastrointestinal symptoms, and laboratory tests were registered. No lifestyle or dietary interventions were applied. RESULTS: Forty-six patients were randomized. Baseline characteristics across groups were comparable; mean weight was 103.6 kg. In patients receiving roflumilast, median weight change was -2.6% and -4% at week 12 and 24, respectively. Corresponding numbers were 0.0% and 1.3% in patients initially allocated to placebo. Reduced appetite was more frequent with active therapy. No changes in blood pressure or laboratory tests were observed. LIMITATIONS: Posthoc analyses and low numbers. CONCLUSION: Oral roflumilast induced weight loss and reduced appetite, which support the growing evidence of roflumilast as an attractive treatment alternative for patients with psoriasis.
引用
- Gyldenløve M, Sørensen JA, Fage S, et al. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO). J Am Acad Dermatol. 2024. PMID: 38431099. doi:10.1016/j.jaad.2024.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。